Natera NTRA recently announced a collaboration with Diakonos Oncology to incorporate its Signatera molecular residual disease test into Diakonos’ DOC-RM Phase I/II investigational immunotherapy trial ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration ...

Natera said the Food and Drug Administration approved its Signatera CDx as a test for bladder cancer. The drug can be used as a companion diagnostic with adjuvant atezolizumab to treat muscle-invasive ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced enrollment of the first ...

NTRA is expanding in Austin with what it says will be the world's largest sequencing capacity as oncology testing demand ...

Jefferies Global Healthcare Conference 2026 June 3, 2026 11:05 AM EDTCompany ParticipantsAndrew Peters - Senior Vice President ...

SOMERVILLE, N.J. - When Scott Jones got winded walking around his house, he assumed it was his age or his heart. Instead, doctors diagnosed the 58-year old with colon cancer. "They said it was an ...

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41.

What Is It, and Why Does It Matter? Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) are prescription immunotherapy medicines used to help the body's immune system ...